
Medicine and Health
Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemia
X. Zhou, W. Lang, et al.
This groundbreaking study by Xinping Zhou and colleagues reveals that circulating tumor DNA (ctDNA) is a promising minimally invasive biomarker for monitoring treatment outcomes in myelodysplastic syndromes and acute myeloid leukemia. The findings highlight the significant correlation between ctDNA concentrations and tumor burden, underscoring its potential in predicting patient survival and detecting early relapses.
~3 min • Beginner • English
Related Publications
Explore these studies to deepen your understanding of the subject.